Softwr

Healthcare · head to head

Paige vs Therapixel

Paige logo

Paige

Healthcare

Digital pathology AI holding the first FDA De Novo authorisation for a pathology algorithm, now part of Tempus

From
On request
Rated
-
Full reviewWebsite
Therapixel logo

Therapixel

Healthcare

French mammography AI with FDA clearances for 2D and tomosynthesis breast screening

From
On request
Rated
-
Full reviewWebsite

The short version

  • Each has a real cost: Paige the FDA authorisation is confined to prostate core needle biopsies, on compatible scanners, viewed through FullFocus, as an adjunct only; every other tissue type and every grading claim is outside that authorisation in the United States.; Therapixel european and American regulatory positions were established under different regimes, and under the EU Medical Device Regulation this class of diagnostic AI faces a higher classification and notified body scrutiny, so European buyers must verify the current MDR certificate and expiry rather than relying on a legacy CE reference.
  • They diverge on capability: Paige covers Paige Prostate Detect, Therapixel covers MammoScreen 2D.
  • Prices and features above were last checked on 1 September 2026.

Where they differ

Only the attributes on which Paige and Therapixel actually diverge.

Attributes where Paige and Therapixel differ
AttributePaigeTherapixel
PlatformsWeb, Cloud, On-premiseWeb

Identical on both: starting price (On request), pricing model (quote), free tier (No), user rating (Not yet rated), category (Healthcare).

What each one covers

Drawn from each product's published feature list. An absence here means we hold no record of it - not that the product lacks it.

Only in Paige

  • Paige Prostate Detect
  • Paige Prostate Grade and Quantify
  • Perineural invasion detection
  • Breast and lymph node applications
  • FullFocus viewer
  • Foundation models
  • OmniScreen
  • Paige Alba

Only in Therapixel

  • MammoScreen 2D
  • MammoScreen DBT
  • One to ten suspicion score
  • Summary report
  • Workstation and PACS delivery
  • Reading workflow configurations

What people use each for

The jobs each tool is most often brought in to do.

Paige

  • A reference laboratory processing high volumes of prostate core needle biopsies where a second read on every case is not staffablenot Therapixel
  • A pathology department already digitised that wants a documented safety net against missed small foci of cancernot Therapixel
  • A hospital laboratory struggling to recruit uropathology subspecialists and needing consistency across generalist reportingnot Therapixel
  • A pharmaceutical company needing consistent biomarker scoring across trial sites rather than site-by-site pathologist variabilitynot Therapixel

Therapixel

  • A European breast screening programme running mandatory double reading that wants to evaluate AI as a concurrent or second reader within what national guidance permitsnot Paige
  • An American breast centre that has moved to tomosynthesis and needs reading support on DBT specifically, which Therapixel holds a clearance fornot Paige
  • A screening service wanting a graded suspicion score rather than a binary flag so readers can calibrate their own thresholdnot Paige
  • A radiology group evaluating multiple mammography AI vendors head to head on their own historic case set before committingnot Paige

Where each one falls short

Documented limitations, not opinions. Every one is a constraint you would hit in normal use.

Paige

  • The FDA authorisation is confined to prostate core needle biopsies, on compatible scanners, viewed through FullFocus, as an adjunct only; every other tissue type and every grading claim is outside that authorisation in the United States.
  • The algorithm is worthless without a digital pathology programme already running, and slide scanning, storage and workflow typically cost far more than the software licence.
  • Tempus acquired Paige in 2025, so the roadmap now competes for attention inside a genomics-led business, and the pathology-only buyer is no longer the primary customer.
  • Scanner compatibility is a hard constraint rather than a preference, and a laboratory with an unsupported scanner fleet cannot use the authorised indication at all.
  • Pricing is per case or per slide and unpublished, so a laboratory cannot model cost per reported case without entering a sales process.

Therapixel

  • European and American regulatory positions were established under different regimes, and under the EU Medical Device Regulation this class of diagnostic AI faces a higher classification and notified body scrutiny, so European buyers must verify the current MDR certificate and expiry rather than relying on a legacy CE reference.
  • MammoScreen does mammography only, so a hospital wanting AI across head CT, chest and breast needs several vendors and several PACS integrations, or an orchestration layer bought from someone else.
  • Therapixel is a small French company competing against Hologic and iCAD, which have incumbency inside the mammography reading workstation, so integration into an American breast centre is more work than it is for the workstation vendor own AI.
  • Detection performance is sensitive to the mammography unit vendor and acquisition protocol, so published results do not transfer between estates and each site needs local validation it must fund itself.
  • Whether AI can substitute for one of two human readers is a national workforce and liability question, not a product capability, so the labour saving that justifies the purchase in one country is not permitted in another.

Pricing, plan by plan

Paige

On request
  • Paige clinical applications$undefined/year
    • Priced per case or per slide analysed under annual agreement
    • Prostate, breast and other applications licensed separately
    • Requires compatible whole slide scanner and the FullFocus viewer for the authorised indication

Therapixel

On request
  • MammoScreen$undefined/year
    • Priced per examination or by annual screening volume
    • 2D and tomosynthesis licensed by the versions cleared for each
    • Cloud or on premises deployment quoted differently

Which should you pick?

Choose Paige if

  • You need paige prostate detect.
  • You work on Web, Cloud, On-premise.
  • You also want paige prostate grade and quantify.
Paige review

Choose Therapixel if

  • You need mammoscreen 2d.
  • You also want mammoscreen dbt.
Therapixel review

Questions people ask

Is Paige or Therapixel better?
Neither clearly leads. Paige starts at On request and Therapixel at On request, and user ratings are close enough to be indistinguishable. Choose on capability and platform support.
Which is cheaper, Paige or Therapixel?
Paige starts at On request and Therapixel at On request.
Does Paige or Therapixel run on more platforms?
Paige runs on Web, Cloud, On-premise. Therapixel runs on Web.
What is Paige best used for?
Paige is most often used for a reference laboratory processing high volumes of prostate core needle biopsies where a second read on every case is not staffable, a pathology department already digitised that wants a documented safety net against missed small foci of cancer, a hospital laboratory struggling to recruit uropathology subspecialists and needing consistency across generalist reporting, a pharmaceutical company needing consistent biomarker scoring across trial sites rather than site-by-site pathologist variability. Of those, a reference laboratory processing high volumes of prostate core needle biopsies where a second read on every case is not staffable and a pathology department already digitised that wants a documented safety net against missed small foci of cancer are not what Therapixel is typically brought in for.
What can Paige do that Therapixel cannot?
Paige covers Paige Prostate Detect, Paige Prostate Grade and Quantify, Perineural invasion detection, Breast and lymph node applications. Therapixel covers MammoScreen 2D, MammoScreen DBT, One to ten suspicion score, Summary report.

Answered from the vendors’ own pages

Paige: What exactly is FDA authorised?

Paige Prostate Detect, as an adjunct for identifying areas of interest on digitised prostate core needle biopsy slides, viewed through the Paige FullFocus viewer on a compatible scanner. Nothing else in the portfolio holds that authorisation in the United States.

Therapixel: Is MammoScreen FDA cleared?

Yes. It holds 510(k) clearance K192854 for two dimensional mammography from July 2020, a November 2021 clearance for digital breast tomosynthesis, and two further clearances in October 2024 for later versions.

Paige: Is the European position broader?

Yes. The Paige Prostate suite including grading and quantification received IVDR certification in 2025, which covers more than the United States authorisation.

Therapixel: Is it CE marked?

Yes, but European buyers should ask specifically for the current certificate under the Medical Device Regulation and its expiry date, because this class of diagnostic AI moved to a higher classification under MDR.

Paige: What did the pivotal study measure?

Pathologist cancer detection on individual slide images improved, with reported reductions in false negative and false positive readings. It measured pathologist performance with the tool, not standalone algorithm accuracy.

Therapixel: What does the one to ten score mean?

It is a graded suspicion score per finding and per study, designed to be integrated alongside a radiologist BI-RADS assessment rather than treated as a positive or negative result.

Paige: Who owns Paige now?

Tempus AI acquired Paige in 2025. Products remain branded Paige.

Therapixel: Does it cover anything besides mammography?

No. It is a mammography product only, including tomosynthesis. Other body regions need a different vendor.

Share

Related pages

More on Paige

More on Therapixel

Keep looking

Other head to heads